Our approach to sustainability may surprise you
Additionally, overuse of rescue medications and uncontrolled patients can unnecessarily add to the environmental burden of treating respiratory conditions.2
Unfortunately, current ways to minimise the carbon footprint of respiratory care do not put patients at the centre.3,4
Environmentally-driven switches to DPIs are often costly, resource-intensive and have the potential to negatively impact disease control.5–7
WE NEED LONG-TERM SOLUTIONS TO SUPPORT THE PLANET, PATIENTS AND THE NHS
In the respiratory healthcare sector, we need to fight climate change without compromising patient care. The path to reaching carbon targets requires a long-term approach focusing on innovation in respiratory management, rather than seeing a device switch as an easy solution.5
In 2019, before NHS carbon targets were set, we began investing €350 million into the development of pMDIs with an environmentally-friendly propellant that can be used across the Chiesi respiratory portfolio.8
It will be available from 2025, well within the timeframe for both UK and NHS plans to reduce carbon emissions by 2030.8–10*
CONTINUING PATIENTS ON CURRENT PRESCRIPTIONS COULD LEAD TO REDUCED CARBON EMISSIONS WITHOUT ADVERSELY AFFECTING PATIENT CONTROL
Innovation and the introduction of environmentally-friendly propellants could be the ideal answer to the environmental challenge facing respiratory care.8,10*
- Waiting for the introduction of environmentally-friendly propellants into our inhaler portfolio has the potential to produce a decrease in carbon emissions while prioritising patient care without disruption to disease control8,10*
- For you and the NHS, the introduction of environmentally-friendly propellants will result in minimal cost and resource demands for the NHS10,11*
AT CHIESI, WE PLEDGE TO OFFER YOU THE CHOICE OF DPI OR pMDI INHALERS FOR YOUR PATIENTS
There is no one right device for all patients and that’s why from 2025, well ahead of the NHS 2030 target, we are introducing low carbon pMDIs into our inhaler portfolio,8,9 so you can choose the device that’s right for your patient and the planet.
Our approach to sustainability may surprise you.
*Data based on hypothetical modelling of carbon emission reductions (non-SABA pMDI switches).10
DPI: dry powder inhaler; pMDI: pressurised metered dose inhaler; SABA: short-acting β2-agonist.
- The Economist Intelligence Unit. Climate change and its impact on lung health: a focus on Europe. Available at: https://impact.economist.com/perspectives/sites/default/files/lon_-_es_-_chiesi_climate_change_lung_health_v6.pdf
- Wilkinson AJK, et al. Thorax. 2021; 76: A19.
- Usmani OS. Ther Clin Risk Manag. 2019; 15: 461–472.
- NHS long term plan. 2019. Available at: https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf
- Attar-Zadeh D, et al. J Health Econ Outcomes Res. 2021; 8(2): 26–34.
- Jenkins D, et al. Poster presented at Clinical Pharmacy Congress (CPC). June 2019; Poster 23.
- Thomas M, et al. BMC Pulmonary Medicine. 2009; 9: 1.
- Every Story Counts. Chiesi Annual & Sustainability Report 2020. Available at: https://www.chiesi.com/en/flipbook.php?url=https://www.chiesi.com/img/annual_report/documenti/44_20210623_chiesi_report_long_eng_def_july_ld.pdf
- NHS Business Services Authority. NHS Business Services Authority declares climate emergency and sets to achieve net-zero greenhouse gas emissions by 2030. Available at: https://media.nhsbsa.nhs.uk/news/nhs-business-services-authority-declares-climate-emergency-and-sets-to-achieve-net-zero-greenhouse-gas-emissions-by-2030#
- Chiesi Data on File (Aequilibria report, pages 58–60).
- Chiesi UK. Data on File.